Tirzepatide for heart health in obese adults with congenital heart disease
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests if tirzepatide can improve heart and metabolic health in overweight or obese adults with congenital heart disease. It may offer a new treatment option for weight loss when lifestyle changes alone haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with congenital heart disease
- Your body mass index (BMI) is between 30 and 40, meaning you are obese or overweight
- You have tried at least 12 months of lifestyle changes (diet and exercise) but lost less than 5% of your body weight
- Your weight has been stable (within 5%) for the past three months
- You have never taken weight-loss medication or had weight-loss surgery
- You are not pregnant, not breastfeeding, and willing to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.
This trial tests if the weight loss medication tirzepatide can help young adults (18–40) with obesity and high blood pressure lower their blood pressure. It compares standard care to weight loss with tirzepatide.
This trial tests whether tirzepatide, a medication for weight and blood sugar, can reduce the chances of atrial fibrillation (an irregular heartbeat) coming back after a heart procedure called catheter ablation in people with overweight or obesity. It may help by addressing weight-related factors that contribute to heart rhythm problems.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.